Ascendis Pharma A/S $ASND Holdings Lifted by Sigma Planning Corp

Sigma Planning Corp raised its position in Ascendis Pharma A/S (NASDAQ:ASND) by 173.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,257 shares of the biotechnology company’s stock after purchasing an additional 3,967 shares during the quarter. Sigma Planning Corp’s holdings in Ascendis Pharma A/S were worth $1,426,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ASND. Allworth Financial LP raised its holdings in shares of Ascendis Pharma A/S by 103.4% during the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 122 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after buying an additional 69 shares during the period. Parallel Advisors LLC grew its holdings in Ascendis Pharma A/S by 94.9% in the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after buying an additional 148 shares in the last quarter. IFP Advisors Inc grew its holdings in Ascendis Pharma A/S by 3,491.7% in the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after buying an additional 419 shares in the last quarter. Finally, Farther Finance Advisors LLC bought a new position in Ascendis Pharma A/S in the 3rd quarter worth approximately $139,000.

Insider Buying and Selling at Ascendis Pharma A/S

In other news, Director Jean-Jacques Bienaimé acquired 2,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was acquired at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the acquisition, the director directly owned 2,900 shares in the company, valued at $714,357. This represents a 222.22% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at $810,570. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Stock Performance

ASND opened at $249.55 on Thursday. The company has a market capitalization of $15.57 billion, a price-to-earnings ratio of 19.36 and a beta of 0.38. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. Ascendis Pharma A/S has a 1-year low of $188.07 and a 1-year high of $282.15. The business has a 50 day moving average price of $242.51 and a two-hundred day moving average price of $237.55.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The firm had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Research analysts predict that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on ASND shares. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Thursday, October 15th. They issued a “buy” rating and a $269.00 target price on the stock. Wedbush reiterated an “outperform” rating and set a $327.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st. Bank of America decreased their price target on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. HC Wainwright set a $344.00 price target on Ascendis Pharma A/S in a report on Thursday, September 10th. Finally, Oppenheimer raised their target price on shares of Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an “outperform” rating in a research note on Tuesday, September 1st. Nineteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $305.95.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.

Its commercial products include SKYTROFA (lonape­gsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.